Insurance companies determine medical necessity for autism services through a comprehensive review process designed to verify that the proposed treatment is essential, effective, and clinically appropriate. The determination is based on the following core criteria:

• Formal Diagnosis: A child must have a formal diagnosis of Autism Spectrum Disorder (ASD), typically defined by the DSM-5, from a licensed healthcare professional (such as a psychologist or developmental pediatrician).
• Functional Impairment: There must be documented evidence that the child faces meaningful challenges in communication, social interaction, or adaptive behavior that affect their safety, learning, or daily family life.
• Expectation of Improvement: The treatment plan must demonstrate a reasonable expectation that Applied Behavior Analysis (ABA) therapy will help the child build skills and reduce problematic behaviors in measurable ways.

Insurers also rely on clinical guidelines from authoritative bodies like the National Institutes of Health (NIH) and the US Surgeon General, which recognize ABA as an evidence-based treatment rather than an experimental or optional service. To make a final determination, insurers review a specific package of documentation, including:

1. Diagnostic Report: Confirms the autism diagnosis using tools like the ADOS.
2. Functional Behavior Assessment (FBA): Provides objective baseline data and identifies the function of target behaviors.
3. Letter of Medical Necessity (LMN): A formal clinical rationale that links the child’s diagnosis to their specific functional impairments.
4. Individualized Treatment Plan: Outlines specific, measurable goals and intervention strategies.